These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH. J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617 [Abstract] [Full Text] [Related]
3. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF. Clin Cancer Res; 2002 Feb; 8(2):514-9. PubMed ID: 11839671 [Abstract] [Full Text] [Related]
4. A quantitative promoter methylation profile of prostate cancer. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D. Clin Cancer Res; 2004 Dec 15; 10(24):8472-8. PubMed ID: 15623627 [Abstract] [Full Text] [Related]
5. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation. Kelavkar UP, Harya NS, Hutzley J, Bacich DJ, Monzon FA, Chandran U, Dhir R, O'Keefe DS. Prostaglandins Other Lipid Mediat; 2007 Jan 15; 82(1-4):185-97. PubMed ID: 17164146 [Abstract] [Full Text] [Related]
13. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Müller SC, von Rücker A. Eur Urol; 2007 Mar 15; 51(3):665-74; discussion 674. PubMed ID: 16956712 [Abstract] [Full Text] [Related]
14. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Sathyanarayana UG, Padar A, Suzuki M, Maruyama R, Shigematsu H, Hsieh JT, Frenkel EP, Gazdar AF. Clin Cancer Res; 2003 Dec 15; 9(17):6395-400. PubMed ID: 14695140 [Abstract] [Full Text] [Related]
18. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. J Cell Biochem; 2004 Feb 15; 91(3):540-52. PubMed ID: 14755684 [Abstract] [Full Text] [Related]
19. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Cancer; 2006 Jan 01; 106(1):79-86. PubMed ID: 16323173 [Abstract] [Full Text] [Related]
20. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Liu L, Yoon JH, Dammann R, Pfeifer GP. Oncogene; 2002 Oct 03; 21(44):6835-40. PubMed ID: 12360410 [Abstract] [Full Text] [Related] Page: [Next] [New Search]